Literature DB >> 19114076

Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.

Stéphanie G Trouche1, Ayodeji Asuni, Sylvie Rouland, Thomas Wisniewski, Blas Frangione, Jean-Michel Verdier, Einar M Sigurdsson, Nadine Mestre-Francés.   

Abstract

We have been developing Abeta derivative vaccines with the objective to improve the safety of Abeta targeting immunotherapy. Our Abeta homologs are designed to have less direct toxicity and to produce a modified immune response compared to Abeta. In extensive mouse studies, all our vaccines have improved cognition in transgenic mice while eliciting different immune responses and reducing brain amyloid burden to a variable degree. While we are continuing to characterize these vaccines in mice, in preparation for studies in old primates and for human trials we assessed their effect in young lemur primates (n=25) that with age develop Abeta plaques and tau aggregates as seen in Alzheimer's disease. In the primates, all the peptides administered with alum adjuvant elicited a moderate to robust anti-Abeta IgM response. Abeta1-42, K6Abeta1-30 and K6Abeta1-30[E(18)E(19)] resulted in a high anti-Abeta IgG response, whereas Abeta1-30[E(18)E(19)] produced a weaker more variable IgG titer. Notably, 22 weeks after the 3rd immunization, IgM and IgG levels in derivative-vaccinated primates were similar to preimmune values whereas Abeta1-42 treated primates maintained a moderate IgG titer. The increase in antibodies that recognized Abeta1-40 often correlated with increase in Abeta1-40 in plasma, which suggests that the antibodies were binding to Abeta in vivo. Interestingly, significant transient weight gain was observed (K6Abeta1-30-, Abeta1-30[E(18)E(19)]- and Abeta1-42-treated) or a trend in the same direction (K6Abeta1-30[E(18)E(19)]-treated, adjuvant controls) following the injections. Based on these findings, we have chosen K6Abeta1-30 for immunizations in old primates as the antibody response to this vaccine was less variable compared to other Abeta derivatives. Our present findings indicate that most of our Abeta derivatives elicit a substantial antibody response in primates, and importantly this effect is reversible which enhances the safety profile of our approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19114076      PMCID: PMC2713060          DOI: 10.1016/j.vaccine.2008.12.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

1.  EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.

Authors:  Vered Lavie; Maria Becker; Rachel Cohen-Kupiec; Iftach Yacoby; Rela Koppel; Manuela Wedenig; Birgit Hutter-Paier; Beka Solomon
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Histological staining of amyloid-beta in mouse brains.

Authors:  Einar M Sigurdsson
Journal:  Methods Mol Biol       Date:  2005

3.  Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus.

Authors:  P Giannakopoulos; S Silhol; V Jallageas; J Mallet; N Bons; C Bouras; P Delaère
Journal:  Acta Neuropathol       Date:  1997-08       Impact factor: 17.088

4.  Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages.

Authors:  Ayodeji A Asuni; Allal Boutajangout; Henrieta Scholtzova; Elin Knudsen; Yong Sheng Li; David Quartermain; Blas Frangione; Thomas Wisniewski; Einar M Sigurdsson
Journal:  Eur J Neurosci       Date:  2006-11       Impact factor: 3.386

Review 5.  Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity.

Authors:  Royce P Vincent; Hutan Ashrafian; Carel W le Roux
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-04-01

6.  Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet.

Authors:  Cynthia A Lemere; Amy Beierschmitt; Melitza Iglesias; Edward T Spooner; Jeanne K Bloom; Jodi F Leverone; Jessica B Zheng; Timothy J Seabrook; Dora Louard; Diana Li; Dennis J Selkoe; Roberta M Palmour; Frank R Ervin
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

7.  [Cerebrospinal fluid proteins: III. Normal values of immunoglobulins G, A and M (variations related to race, sex and age)].

Authors:  L M Vermes
Journal:  Arq Neuropsiquiatr       Date:  1983-03       Impact factor: 1.420

Review 8.  Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.

Authors:  Frauke Neff; Xing Wei; Carmen Nölker; Michael Bacher; Yansheng Du; Richard Dodel
Journal:  Autoimmun Rev       Date:  2008-05-01       Impact factor: 9.754

9.  Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

Authors:  Marcel Maier; Timothy J Seabrook; Noel D Lazo; Liying Jiang; Pritam Das; Christopher Janus; Cynthia A Lemere
Journal:  J Neurosci       Date:  2006-05-03       Impact factor: 6.167

10.  Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.

Authors:  Jun Zhou; Maria I Fonseca; Rakez Kayed; Irma Hernandez; Scott D Webster; Ozkan Yazan; David H Cribbs; Charles G Glabe; Andrea J Tenner
Journal:  J Neuroinflammation       Date:  2005-12-07       Impact factor: 8.322

View more
  15 in total

1.  Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.

Authors:  Nelly Joseph-Mathurin; Olène Dorieux; Stéphanie G Trouche; Allal Boutajangout; Audrey Kraska; Pascaline Fontès; Jean-Michel Verdier; Einar M Sigurdsson; Nadine Mestre-Francés; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2013-06-22       Impact factor: 4.673

2.  Age-associated cerebral atrophy in mouse lemur primates.

Authors:  Audrey Kraska; Olene Dorieux; Jean-Luc Picq; Fanny Petit; Emmanuel Bourrin; Evelyne Chenu; Andreas Volk; Martine Perret; Philippe Hantraye; Nadine Mestre-Frances; Fabienne Aujard; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2009-06-28       Impact factor: 4.673

Review 3.  Amyloid-beta immunotherapy for Alzheimer's disease.

Authors:  H J Fu; B Liu; J L Frost; C A Lemere
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition.

Authors:  Maggie Roy; Cécile Cardoso; Olène Dorieux; Carole Malgorn; Stéphane Epelbaum; Fanny Petit; Audrey Kraska; Emmanuel Brouillet; Benoît Delatour; Martine Perret; Fabienne Aujard; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2014-07-18       Impact factor: 4.673

5.  Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.

Authors:  Elina Zotova; James Ar Nicoll; Raj Kalaria; Clive Holmes; Delphine Boche
Journal:  Alzheimers Res Ther       Date:  2010-01-22       Impact factor: 6.982

6.  Distinct transcriptome expression of the temporal cortex of the primate Microcebus murinus during brain aging versus Alzheimer's disease-like pathology.

Authors:  Ronza Abdel Rassoul; Sabine Alves; Véronique Pantesco; John De Vos; Bernard Michel; Martine Perret; Nadine Mestre-Francés; Jean-Michel Verdier; Gina Devau
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

Review 7.  AD vaccines: conclusions and future directions.

Authors:  Thomas Wisniewski
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

Review 8.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

9.  Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate.

Authors:  Nadine Mestre-Francés; Nicolas Serratrice; Aurélie Gennetier; Gina Devau; Sandra Cobo; Stéphanie G Trouche; Pascaline Fontès; Charleine Zussy; Philippe De Deurwaerdere; Sara Salinas; Franck Jd Mennechet; Julien Dusonchet; Bernard L Schneider; Isabella Saggio; Vasiliki Kalatzis; M Rosario Luquin-Piudo; Jean-Michel Verdier; Eric J Kremer
Journal:  JCI Insight       Date:  2018-07-26

10.  Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.

Authors:  Allal Boutajangout; Fernando Goni; Elin Knudsen; Fernanda Schreiber; Ayodeji Asuni; David Quartermain; Blas Frangione; Alejandro Chabalgoity; Thomas Wisniewski; Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.